153 related articles for article (PubMed ID: 33021155)
41. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours.
Pires I; Garcia A; Prada J; Queiroga FL
J Comp Pathol; 2010; 143(2-3):142-9. PubMed ID: 20207364
[TBL] [Abstract][Full Text] [Related]
42. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Shibata Y; Hara T; Nagano J; Nakamura N; Ohno T; Ninomiya S; Ito H; Tanaka T; Saito K; Seishima M; Shimizu M; Moriwaki H; Tsurumi H
PLoS One; 2016; 11(1):e0146279. PubMed ID: 26727596
[TBL] [Abstract][Full Text] [Related]
43. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
[TBL] [Abstract][Full Text] [Related]
44. Expression of indoleamine 2,3-dioxygenase in pregnant mice correlates with CD4+CD25+Foxp3+ T regulatory cells.
Yu LL; Zhang YH; Zhao FX
Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1722-1728. PubMed ID: 28485810
[TBL] [Abstract][Full Text] [Related]
45. Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival.
Rubel F; Kern JS; Technau-Hafsi K; Uhrich S; Thoma K; Häcker G; von Bubnoff N; Meiss F; von Bubnoff D
J Invest Dermatol; 2018 Mar; 138(3):679-687. PubMed ID: 29054599
[TBL] [Abstract][Full Text] [Related]
46. Abnormal Expression of Indoleamine 2, 3-Dioxygenase in Human Recurrent Miscarriage.
Wei H; Liu S; Lian R; Huang C; Li Y; Chen L; Zeng Y
Reprod Sci; 2020 Aug; 27(8):1656-1664. PubMed ID: 32430712
[TBL] [Abstract][Full Text] [Related]
47. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
[TBL] [Abstract][Full Text] [Related]
48. Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients.
Asghar K; Loya A; Rana IA; Bakar MA; Farooq A; Tahseen M; Ishaq M; Masood I; Rashid MU
World J Clin Oncol; 2020 Dec; 11(12):1018-1028. PubMed ID: 33437664
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical evaluation of immune cell infiltration in canine gliomas.
Krane GA; O'Dea CA; Malarkey DE; Miller AD; Miller CR; Tokarz DA; Jensen HL; Janardhan KS; Shockley KR; Flagler N; Rainess BA; Mariani CL
Vet Pathol; 2021 Sep; 58(5):952-963. PubMed ID: 34196247
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma.
Sulaimon S; Kitchell B; Ehrhart E
J Comp Pathol; 2002; 127(2-3):162-8. PubMed ID: 12354527
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of Soluble CTLA-4-Fc in the Inhibition of Bone Marrow T-Cell Activation in Context of Indoleamine 2.3-Dioxygenase (IDO) and CD4
Massalska M; Ciechomska M; Kuca-Warnawin E; Burakowski T; Kornatka A; Radzikowska A; Pawlak D; Muz B; Loniewska-Lwowska A; Palucha A; Maldyk P; Maslinski W
J Inflamm Res; 2022; 15():6813-6829. PubMed ID: 36578517
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical Expression of FXR1 in Canine Normal Tissues and Melanomas.
Nordio L; Marques AT; Lecchi C; Luciano AM; Stefanello D; Giudice C
J Histochem Cytochem; 2018 Aug; 66(8):585-593. PubMed ID: 29608406
[TBL] [Abstract][Full Text] [Related]
53. The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
Nishi M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Ishikawa D; Wada Y; Shimada M
Anticancer Res; 2018 Jun; 38(6):3387-3392. PubMed ID: 29848687
[TBL] [Abstract][Full Text] [Related]
54. Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Wang H; Xia Y; Yu J; Guan H; Wu Z; Ban D; Wang M
HLA; 2019 Jul; 94(1):39-48. PubMed ID: 30953385
[TBL] [Abstract][Full Text] [Related]
55. Indoleamine 2,3-dioxygenase and foxp3 expression in skin rejection of human hand allografts.
Hautz T; Brandacher G; Zelger B; Müller HG; Lee AW; Fuchs D; Margreiter R; Schneeberger S
Transplant Proc; 2009 Mar; 41(2):509-12. PubMed ID: 19328914
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of local immunosuppression in cutaneous melanoma.
Polak ME; Borthwick NJ; Gabriel FG; Johnson P; Higgins B; Hurren J; McCormick D; Jager MJ; Cree IA
Br J Cancer; 2007 Jun; 96(12):1879-87. PubMed ID: 17565341
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical detection of melanoma-associated antigens on formalin-fixed, paraffin-embedded canine tumors.
Berrington AJ; Jimbow K; Haines DM
Vet Pathol; 1994 Jul; 31(4):455-61. PubMed ID: 7941235
[TBL] [Abstract][Full Text] [Related]
58. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
Stålhammar G; Seregard S; Grossniklaus HE
Cancer Med; 2019 Jun; 8(6):2784-2792. PubMed ID: 30993893
[TBL] [Abstract][Full Text] [Related]
59. Galectin-3 Expression Correlates with Post-surgical Survival in Canine Oral Melanomas.
Vargas THM; Pulz LH; Ferro DG; Sobral RA; Venturini MAFA; Corrêa HL; Strefezzi RF
J Comp Pathol; 2019 Nov; 173():49-57. PubMed ID: 31812173
[TBL] [Abstract][Full Text] [Related]
60. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
